Global IP Battle: Drug Pricing, Reimbursement Policies Take Center Stage
Executive Summary
USTR's 2018 Special 301 Report moves two countries to Priority Watch List in part because of their pricing policies; AAM says focus should be on government reimbursement rather than extending IP protection.
You may also be interested in...
As Calls For Patent Sharing To Fight Pandemic Intensify, Manufacturing May Be Bigger Issue
Scientists and lawyers ask companies to temporarily license their IP for free, as others advocate compulsory licenses; real issue may be the ability to make a COVID-19 treatment or vaccine widely available.
Pfizer, Gilead Emails Reveal Behind-The-Scenes Battle Over Malaysia's Drug Pricing, Compulsory Licensing Policies
Gilead sought the US Trade Representative's intervention to halt sofosbuvir compulsory license, while Pfizer complained about Malaysia regulation requiring disclosure of prices throughout the pharmaceutical supply chain.
US-Mexico-Canada Trade Agreement Sets 10-Year Floor For Biologics Market Exclusivity
USA's 12-year-plus scheme won't change, but Canada and Mexico must offer sponsors more than previously; biosimilar industry bemoans lack of incentives for competition. Trade pact also specifies damages award options and links regulatory review to patent disputes.